ReviewTherapeutics and clinical risk management2020
Behçet's Disease in Children: Diagnostic and Management Challenges.
Review in Therapeutics and clinical risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.Frontiers in neurology · 2022Pooled it
- Predictive role of inflammatory indexes in systemic manifestations of pediatric Behçet's disease.Annals of medicine · 2026Article
- Tree-based machine learning models recover rule-based flare labels from virtual symptom diaries in pediatric Behçet's disease: an in silico proof-of-concept study.Rheumatology international · 2026Article
- Mucocutaneous-Predominant Pediatric Behçet's Disease With Recurrent Oral and Genital Ulceration: A Case Report.Clinical case reports · 2026Article
- Juvenile Behçet's disease 2014-2024: multicenter study in Colombia.Pediatric rheumatology online journal · 2026Article
- Ocular Manifestations of Pediatric Behçet's Disease.Clinical medicine & research · 2025Review
- Unraveling the complexities of pediatric Behçet's disease clusters.World journal of pediatrics : WJP · 2025Article
- Article
- Bilateral optic neuritis as an atypical presentation of juvenile Behcet syndrome: A case report.eNeurologicalSci · 2025Article
- Clinical heterogeneity and five phenotypes identified in pediatric Behçet's syndrome: a cohort study from Shanghai Behçet's syndrome database.World journal of pediatrics : WJP · 2024Article
- Challenges and opportunities in transitional care process in Behçet's syndrome.Frontiers in medicine · 2024Article
- Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- Cerebral venous thrombosis in adolescence: Looking beyond the obvious.International journal of pediatrics & adolescent medicine · 2022Article
- Recurrent reactive non-sexually related acute genital ulcers: a risk factor for Behcet's disease?Acta bio-medica : Atenei Parmensis · 2022Article
- Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022Review
- Behçet uveitis: Current practice and future perspectives.Frontiers in medicine · 2022Review
- New insights on multigenic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2022Review
- Case report and analysis: Behçet's disease with lower extremity vein thrombosis and pseudoaneurysm.Frontiers in immunology · 2022Article
- Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report.Materia socio-medica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's Disease (BD) is an inflammatory disease of unknown etiology with multisystemic involvement, being the main clinical manifestations represented by recurrent oral and genital ulcerations and uveitis. The disease has typically a chronic-relapsing course and may cause significant morbidity and mortality due to eye, vascular and neurological involvement. Although BD is more frequently diagnosed in adulthood, the disease onset can also be in pediatric age. Pediatric-onset BD is commonly featured by an incomplete clinical picture, and therefore the diagnosis represents a considerable clinical challenge for the physicians. The first classification criteria for pediatric BD, based on a scoring system, have been proposed few years ago. This work focuses on the main difficulties concerning both the diagnostic approach and the treatment of BD in pediatric age. The recommendation for the treatment of pediatric BD has been recently updated and allowed a considerable improvement of the therapeutic strategies. In particular, the use of anti-TNFα drugs as a second-line option for refractory BD, and as a first-line treatment in severe ocular and neurological involvement, has demonstrated to be effective in improving the outcome of BD patients. The knowledge about the molecular pathogenesis is progressively increasing, showing that BD shares common features with autoimmune and autoinflammatory disorders, and thus leading to the use of new biologic agents targeting the main mediators involved in the determination of BD. Anti-IL-17, anti-IL-23, anti-IL-1 and anti-IL-6 agents have shown promising results for the treatment of refractory BD in clinical trials and will represent an important alternative for the therapeutic approach to the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.